Abstract 1553P
Background
Production of IL6 by the tumor stroma of esophageal adenocarcinoma (EAC) causes epithelial-to-mesenchymal transition of tumor cells and resistance to chemoradiation (Ebbing et al. 2019). Serum ADAM12 protein levels measure stroma activity (Veenstra et al. 2018) whilst IL6 and IL6R monitor IL6 inhibition (Nishimoto et al. 2008). Here, we aim to demonstrate that targeting stroma with tocilizumab in EAC patients increases efficacy of chemoradiation.
Methods
This was a multicenter, randomized, open label, phase II proof-of-concept trial in 48 patients with resectable EAC. Patients were stratified for serum ADAM12 (cutoff of 203 pg/mL) and randomized for standard of care chemoradiation according to the CROSS regimen or addition of tocilizumab to standard of care, followed by surgery. Tocilizumab 8 mg/kg with a maximum of 800 mg was given intravenously for three cycles. Serum ADAM12, IL6 and IL6R was measured at baseline, during treatment, at resection and three months thereafter. Primary endpoint was histopathological response to chemoradiation according to the Mandard score.
Results
After inclusion of 36 patients, the trial was discontinued due to safety concerns. Perforation of the esophageal wall was observed in 3/20 (15%) of patients in the intervention arm compared to 0/16 (0%) in the control arm. There was no significant difference in Mandard score between treatment arms (p = 1.000). Patients treated with tocilizumab had significantly higher serum levels of IL6 and IL6R during treatment (p < 0.0001). Baseline ADAM12 was not associated with histopathological response to tocilizumab (p = 0.672). There was no difference in serum ADAM12 levels over time between treatment arms.
Conclusions
Addition of tocilizumab to neoadjuvant chemoradiation in patients with EAC is unsafe and should not be considered for clinical practice. Potentially, concurrent inhibition of IL6 impairs wound healing whilst chemoradiation obliviates the tumor in the esophageal wall, increasing the risk for perforation. We plan to investigate this hypothesis with RNA sequencing, immunohistochemistry, cytokine profiling, and flow cytometry of peripheral blood mononuclear cells and tumor biopsies.
Clinical trial identification
NCT04554771.
Editorial acknowledgement
Legal entity responsible for the study
Amsterdam UMC, location AMC.
Funding
Oncode Institute.
Disclosure
M. van Berge Henegouwen: Financial Interests, Institutional, Advisory Role, Consultant, unrelated to present study: Mylan, Johnson & Johnson, Alesi Surgical, B. Braun, Medtronic; Financial Interests, Institutional, Funding, Unrestricted, unrelated to present study: Stryker. R.E. Pouw: Financial Interests, Institutional, Advisory Role, Consultant: MicroTech Europe, Medtronic BV.; Financial Interests, Institutional, Invited Speaker: Pentax; Financial Interests, Institutional, Advisory Board: EsoCap AG. N.C. van Grieken: Financial Interests, Institutional, Advisory Board, Unrelated to present study: Bristol Myers Squibb, Merck Sharp & Dohme. J. Medema: Financial Interests, Institutional, Advisory Role, Unrelated to present study: AbbVie. S. Derks: Financial Interests, Institutional, Advisory Role, Unrelated to the present study: Bristol Meyers Squibb; Financial Interests, Institutional, Funding, Unrelated to the present study: Incyte; Financial Interests, Institutional, Invited Speaker, Unrelated to the present study: Benecke, Medtalks, Novartis, Servier. M.F. Bijlsma: Financial Interests, Institutional, Funding, Unrelated to present study: Celgene, Lead Pharma; Financial Interests, Institutional, Advisory Role, Consultant: Servier. H.W.M. Van Laarhoven: Financial Interests, Institutional, Advisory Board: BMS, MSD; Financial Interests, Personal, Invited Speaker: Lilly; Financial Interests, Institutional, Writing Engagement: Nordic Pharma; Financial Interests, Institutional, Invited Speaker: Servier; Financial Interests, Institutional, Research Grant, REPEAT study: Bayer; Financial Interests, Institutional, Research Grant: BMS, Philips; Financial Interests, Institutional, Local PI, FRACTION study: BMS; Financial Interests, Institutional, Research Grant, ACTION study: Celgene; Financial Interests, Institutional, Research Grant, DECO study: Janssen; Financial Interests, Institutional, Local PI, RAINFALL study: Lilly; Financial Interests, Institutional, Local PI, KEYNOTE 062 and KEYNOTE 181 study: Merck/MSD; Financial Interests, Institutional, Research Grant, SOX study: Nordic Pharma; Financial Interests, Institutional, Research Grant, TRAP study, PERFECT study; local PI of JACOB study: Roche; Financial Interests, Institutional, Research Grant, LyRICX study: Servier; Financial Interests, Institutional, Research Grant, TAPESTRY study: Merck; Financial Interests, Institutional, Research Grant, Research money and investigational product: Incyte; Non-Financial Interests, Institutional, Product Samples, For all clinical study mentioned, study medication is provided: See 'research funding'. All other authors have declared no conflicts of interest.
Resources from the same session
1554P - Clinical Impact of ERBB2 copy number and tumor mutation burden (TMB) in patients with HER2- positive advanced gastric cancer treated by nivolumab (N-mab) plus trastuzumab (T-mab) and standard chemotherapy
Presenter: Hirokazu Shoji
Session: Poster session 21
1555P - Cell-free DNA analysis in patients with metastatic gastroesophageal adenocarcinoma: Preliminary results of the REGIRI - PRODIGE 58 ancillary study
Presenter: Alexandre Harlé
Session: Poster session 21
1556P - Pharmacokinetics, pharmacodynamics and exposure response analyses of osemitamab in patients with locally advanced or metastatic solid tumors
Presenter: Lin Shen
Session: Poster session 21
1557P - Single-cell RNA-seq dissecting the initiating liver metastasis cells and liver metastatic microenvironment in gastric cancer
Presenter: Shu-yue Zheng
Session: Poster session 21
1558P - Preoperative pembrolizumab plus chemotherapy for resectable esophageal squamous cell carcinoma (ESCC): The phase II Keystone-001 trial
Presenter: hongjing jiang
Session: Poster session 21
1559P - PD-L1 expression as a negative predictive biomarker in advanced esophageal squamous cell cancer treated with chemotherapy alone: A KMSubtraction derived analysis
Presenter: Manavi Sachdeva
Session: Poster session 21
1560P - Osemitamab (TST001): An ADCC enhanced humanized anti-CLDN18.2 mab, demonstrated improved efficacy in combination with anti-PD-L1/PD-1 mab and oxaliplatin/5-FU in preclinical tumor models
Presenter: Xueming Qian
Session: Poster session 21
1561P - APC mutation (mt.), MYC, and GATA6 amplifications (amp.) were associated with worse survival in HER2-positive advanced gastric cancer patients treated with S-1/capecitabine plus oxaliplatin combined with trastuzumab (T-mab) and nivolumab (N-mab)
Presenter: Takeru Wakatsuki
Session: Poster session 21
1562P - Claudin 18.2 expression in resected gastric cancer
Presenter: Mitsuhiro Furuta
Session: Poster session 21
1563P - Tumor-intrinsic subtypes of esophageal adenocarcinoma associate cellular phenotypes with responses to therapy
Presenter: Dionne Blangé
Session: Poster session 21